Treatment of Excessive Bleeding in Jehovah's Witness Patients after Cardiac Surgery with Recombinant Factor VIIa (NovoSeven®)

This publication has 15 references indexed in Scilit:

• Recombinant Activated Factor VII for Adjunctive Hemorrhage Control in Trauma
  Published by Wolters Kluwer Health ,2001
• Use of recombinant factor VIIa in hereditary bleeding disorders
  Current Opinion in Hematology, 2001
• An Effective Treatment of Severe Intractable Bleeding After Valve Repair by One Single Dose of Activated Recombinant Factor VII
  Anesthesia & Analgesia, 2001
• REDUCED TRANSFUSION REQUIREMENTS BY RECOMBINANT FACTOR VIIa IN ORTHOTOPIC LIVER TRANSPLANTATION
  Transplantation, 2001
• NovoSeven® as a universal haemostatic agent
  Blood Coagulation & Fibrinolysis, 2000
• The effect of the administration of recombinant activated factor VII (NovoSeven®) on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: the PROSE study
  Blood Coagulation & Fibrinolysis, 2000
• Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery
  Blood Coagulation & Fibrinolysis, 2000
• Recombinant factor VIIa for intracranial haemorrhage in a Jehovahʼs Witness with severe haemophilia A and factor VIII inhibitors
  Blood Coagulation & Fibrinolysis, 1993
• The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor.
  Journal of Clinical Investigation, 1993
• Management of the Severely Anemic Patient Who Refuses Transfusion: Lessons Learned during the Care of a Jehovah's Witness
  Annals of Internal Medicine, 1992